1. P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis. (25th January 2019) Authors: Dulai, P S; Singh, S; Vande Casteele, N; Meserve, J; Winters, A; Chablaney, S; Aniwan, S; Shashi, P; Kochhar, G; Weiss, A; Koliani-Pace, J L; Gao, Y; Boland, B S; Chang, J T; Faleck, D; Hirten, R; Ungaro, R; Lukin, D; Sultan, K; Hudesman, D Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S433 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP053 Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis. (16th January 2018) Authors: Hudesman, D; Chang, S; Shashi, P; Winters, A; Chablaney, S; Meserve, J; Weiss, A; Aniwan, S; Faleck, D; Koliani-Pace, J L; Kochhar, G; Boland, B; Singh, S; Hirten, R; Shmidt, E; Lasch, K; Luo, M; Bohm, M; Sagi, S V; Fischer, M Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S067 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP006 A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease. (16th January 2018) Authors: Meserve, J; Aniwan, S; Koliani-Pace, J L; Shashi, P; Weiss, A; Faleck, D; Winters, A; Chablaney, S; Kochhar, G; Boland, B; Singh, S; Hirten, R; Shmidt, E; Bohm, M; Sagi, S V; Fischer, M; Lukin, D; Hudesman, D; Chang, S; Sultan, K Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S034 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn's disease but not ulcerative colitis: a multi-centre consortium analysis. (16th January 2018) Authors: Faleck, D; Winters, A; Chablaney, S; Shashi, P; Meserve, J; Weiss, A; Aniwan, S; Koliani-Pace, J L; Kochhar, G; Boland, B; Singh, S; Hirten, R; Shmidt, E; Lasch, K; Luo, M; Bohm, M; Sagi, S V; Fischer, M; Hudesman, D; Chang, S Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S066 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. (16th January 2018) Authors: Lukin, D; Weiss, A; Aniwan, S; Kadire, S; Tran, G; Rahal, M; Faleck, D; Winters, A; Chablaney, S; Meserve, J; Kochhar, G; Shashi, P; Koliani-Pace, J L; Bohm, M; Sagi, S V; Fischer, M; Boland, B; Singh, S; Hirten, R; Shmidt, E Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S036 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Erectile Dysfunction Is Highly Prevalent in Men With Newly Diagnosed Inflammatory Bowel Disease. Issue 8 (17th July 2019) Authors: Shmidt, E; Suárez-Fariñas, M; Mallette, M; Moniz, H; Bright, R; Shah, S A; Merrick, M; Shapiro, J; Xu, F; Saha, S; Sands, B E Journal: Inflammatory bowel diseases Issue: Volume 25:Issue 8(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗